CTIS2023-509278-41-00招募中1 期
Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody - FORTplus
niversitaetsklinikum Heidelberg AöR0 个研究点目标入组 130 人开始时间: 2023年12月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Centrally reviewed CD20-positive follicular lymphoma grade 1/2 or 3a based on WHO classification (2016), Adequate contraception for men and women of childbearing age during therapy and 18 months thereafter, Untreated (radiation-, chemo- or immunotherapy) nodal follicular lymphoma (including involvement of Waldeyer´s ring), Age: =18 years, ECOG: 0-2, Stage: clinical stage I or II (Ann Arbor classification) based on FDG-PET Staging, Risk profile: Largest diameter of the lymphoma = 7 cm (sectional images), Written informed consent and willingness to cooperate during the course of the trial, Adequate bone marrow capacity: ANC = 1.5 x 103/ml, thrombocytes = 100000 x 10 3/ml, hemoglobin = 10 g/dL, Capability to understand the intention and the consequences of the clinical trial
排除标准
- •Extra nodal manifestation of follicular lymphoma, AST or ALT > 2.5 × ULN, Total bilirubin = 1.5 × ULN, INR > 1.5 × ULN, PTT or aPTT > 1.5 × the ULN, Secondary cancer in the patient's medical history (exclusion: basalioma, spinalioma, melanoma in situ, bladder cancer T1a, non-metastasized solid tumor in constant remission, which was diagnosed >3 years ago), Serious disease interfering with a regular therapy according to the study protocol, e.g: congenital or acquired immune-deficiency syndromes, active infections including viral hepatitis, uncontrolled concomitant diseases including significant cardiovascular or pulmonary disease, Severe psychiatric disease, Pregnancy / lactation, Known hypersensitivity against Obinutuzumab or Rituximab drugs with similar chemical structure or any other additive of the pharmaceutical formula of the study drug, Active hepatitis B infection (inactive hepatitis B infections require additional prophylactic anti-viral medication for 1 year (e.g. Lamivudin, Entecavir, Tenofovir), Participation in another interventional trial or follow-up period of a competing trial which can influence the results of this current trial, Creatinine > 1.5 times the upper limit of normal (ULN) (unless creatinine clearance normal), or calculated creatinine clearance < 40 mL/min
研究者
相似试验
进行中（未招募）
1 期
Therapy of follicular lymphoma with radiotherapy an antibodynodal follicular lymphoma grade 1 or grade 2 in the clinical stage I or II (Ann Arbor classification)MedDRA version: 23.0Level: PTClassification code 10029603Term: Non-Hodgkin's lymphoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000362-15-DERuprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial130
已完成
2 期
Short Chemo Radio Immunotherapy in Follicular Lymphoma Trial of Y-90 ibritumomab tiuxetan (Zevalin®) as therapy for first and second relapse in follicular lymphomaFollicular lymphomaCancerISRCTN44808098Southampton University Hospitals NHS Trust (UK)50
尚未招募
Unknown
Evaluate the use of Early-Stage Follicular Lymphoma International ImmunoTherapy Registry and initial analysis plan to describe progression-free survival for patients with stage I-II follicular lymphoma treated with radiotherapy alone compared with radiotherapy plus immunotherapy.ACTRN12624000669594Peter MacCallum Cancer Centre300
招募中
3 期
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 AntibodyEarly Stage Follicular Lymphoma WHO Grade 1/2 or 3aNCT05045664Heidelberg University100
Unknown
2 期
R2 in the Treatment of Follicular LymphomaFollicular LymphomaNCT03715309Ruijin Hospital115